Literature DB >> 16419558

Residential substance user treatment programs as venues for HCV pharmacological treatment: client and staff perspectives.

Shiela M Strauss1, Janetta M Astone, Corrine Munoz-Plaza, Holly Hagan, Don Des Jarlais.   

Abstract

Hepatitis C virus (HCV) infection is highly prevalent among drug users. While there are antiviral medications available to combat the virus, the medication regimen is quite arduous, presenting special issues for drug users. We examined the challenges and benefits of using residential substance user treatment programs as venues for clients to undergo HCV medication regimens. Analyses of qualitative data collected from clients and staff in 2003 at four residential substance user treatment programs in the U.S. indicate that challenges primarily include issues involving the medications' side effects, and both financial and communication concerns. Benefits especially involve clients' feelings that they are being proactive in addressing health issues in an environment that provides much-needed support. Findings illuminate the complex issues involved for both clients and the programs, and some steps that programs can take to better support HCV-infected clients regarding HCV medication concerns.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16419558     DOI: 10.1080/10826080500261097

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  2 in total

1.  Enhancing Drug Treatment Program Staff's Self-Efficacy to Support Patients' HCV Needs.

Authors:  Shiela M Strauss; Corrine Munoz-Plaza; Mary T Rosedale; David M Rindskopf; Joseph Lunievicz
Journal:  J Soc Work Pract Addict       Date:  2011-01-01

Review 2.  Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.

Authors:  Zachary C Rich; Carissa Chu; Jessica Mao; Kali Zhou; Weiping Cai; Qingyan Ma; Paul Volberding; Joseph D Tucker
Journal:  BMC Public Health       Date:  2016-09-20       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.